Liege, Belgium, November 29, 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the holding of its Investor Day today at its R&D and production center, the Mithra CDMO in Flémalle, Belgium.

As of 9:00 am CET, all presentations can be simultaneously followed by webcast on the Company’s website or by clicking here. A replay will also be available via this same link shortly after the end of the conference.

Information on the Total Number of Voting Rights Following the Completion of the LDA Capital Increase

Liege, Belgium, 10 November 2021 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 314,162 new shares today for a total amount of EUR 5,727,177 following the Put Option Notice issued on July 2, 2021 in the framework of LDA capital.

Mithra Announces Estelle® Approval in Russia

Liege, Belgium, 16 September 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce that the Russian Medicines Agency (Roszdravnadzor) has approved the registration application for the novel combined oral contraceptive Estelle® containing 15mg estetrol (E4) and 3 mg drospirenone (DRSP).

Developed by Mithra, Estelle® is the first and only pill containing estetrol (E4), a naturally occurring native estrogen produced in the human body during pregnancy.

Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 02 July 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the issuance of a put option notice, according to the terms of the capital commitment agreement signed with LDA Capital Limited on April 24, 20201 . Under the terms of this agreement, LDA Capital commits an amount of up to EUR 50 million in cash within a maximum of three years in exchange for new ordinary shares in Mithra. This is the second put option notice related to this agreement, after the first issued on May 29, 2020.

Mithra’s General Meeting of Shareholders Approves the Renewal of its Board of Directors

Liege, Belgium, 20 May 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today held its Annual General Meeting of securities holders. All agenda items put to vote were approved, including the appointment of Directors for a two-year-mandate.

 

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 6 May 2021 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 1,023,000 new shares on May 6, 2021 for a total amount of EUR 3,500,520 as the result of the exercise of 620 subscription rights (warrants) pursuant to the warrant plan initiated on March 2, 2015.

Mithra takes note of François Fornieri’s indictment

Liege, Belgium, 28 avril 2021 – 21:15 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces having been informed of François Fornieri’s indictment of alleged insider dealing charges following his audition held in Liège today by the federal judicial police.

Mithra reminds that since February 04, 2021, Mr. Fornieri no longer performs any management functions within the company and that the CEO function is now assumed by Mr Leon Van Rompay. Therefore, the indictment of Mr. Fornieri does not have any impact on the operational management of the company’s activities. Following the recent approvals obtained for its contraceptive product Estelle®, Mithra is more than ever focused on its ambitious objectives.

Mithra Releases 2020 Annual Report and Invitation to its Securities holders’ Meeting

Liege, Belgium, 20 April 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2020 Annual Report and the invitation to its ordinary and extraordinary general meeting of securities holders.

2020 Annual Report

The Annual Report which outlines Mithra’s achievements in 2020 includes the following information:

  • Overview of Mithra’s R&D pipeline and Letter to Shareholders;
  • Highlights of Mithra’s Strategy and Outlook for 2021;
  • Management Report;
  • Remuneration Report;
  • Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website report2020.mithra.com or on investors.mithra.com. In case of interpretation differences, the French version will prevail.


General Shareholders’ meeting

Mithra is pleased to invite its securities holders to its ordinary and extraordinary general shareholder’s meeting that will be held on Thursday May 20 2021 at 2:00 PM (CEST).

The notice for the General Shareholder’s Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Mithra Reports Full Year 2020 Financial Results

  • Strengthening of the financial resources and balance sheet structure via various funding transactions for an amount of EUR 260 million, diversifying the sources of financing
  • Record cash position of EUR 138.7 million allowing the continuation of our Business Development strategy for Donesta® and R&D projects beyond Women’s Health, notably in Covid-19 treatment
  • Licensing milestones from backlog contracts signed for Estelle® amount to more than EUR 450 million, with more than EUR 300 million cash to still be collected
  • First marketing authorization (MA) obtained for lead asset Estelle® in Canada, with other MA expected in Europe and the United States in the first half of 2021

 Liege, Belgium, 09 March 2021 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2020, prepared in accordance with IFRS.

Mithra to Host Webcast for 2020 Financial Results on 9 March 2021

Liege, Belgium, 04 March 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces that it will host a live webcast on Tuesday, 9 March 2021 at 09:30 CET to present its 2020 financial and operating results.

The live webcast can be accessed on the Mithra website or by clicking here.

To participate to the conference call, please register on this link,

A replay of the webcast will be available on the Mithra investor’s website shortly after the close of the call.